Purple Biotech Reports Third Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Nov 15, 2024
Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024
New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated with CM24 novel targets
Read more at globenewswire.com
